Antimalarial drug discovery: Efficacy models for compound screening

被引：597

作者：

Fidock, DA

Rosenthal, PJ

Croft, SL

Brun, R

Nwaka, S

机构：

[1] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA

[2] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[3] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England

[4] Swiss Trop Inst, Dept Med Parasitol & Infect Biol, CH-4002 Basel, Switzerland

[5] Med Malaria Venture, CH-1215 Geneva 15, Switzerland

来源：

NATURE REVIEWS DRUG DISCOVERY | 2004年 / 3卷 / 06期

关键词：

D O I：

10.1038/nrd1416

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Increased efforts in antimalarial drug discovery are urgently needed. The goal must be to develop safe and affordable new drugs to counter the spread of malaria parasites that are resistant to existing agents. Drug efficacy, pharmacology and toxicity are important parameters in the selection of compounds for development, yet little attempt has been made to review and standardize antimalarial drug-efficacy screens. Here, we suggest different in vitro and in vivo screens for antimalarial drug discovery and recommend a streamlined process for evaluating new compounds on the path from drug discovery to development.

引用

页码：509 / 520

页数：12

共 108 条

[1] Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children:: a randomised, multicentre trial [J].